Updated Colorectal Cancer Guidelines Endorse New Stool Tests, Recommend Limited Use of Blood Tests

Why It Matters

By expanding non‑invasive stool options while limiting less‑effective blood tests, the guidelines aim to boost screening adherence and reduce colorectal cancer mortality, particularly in younger adults where incidence is rising.

Key Takeaways

• ACS endorses next‑gen DNA stool test for average‑risk screening
• New RNA stool test joins preferred colorectal cancer screening menu
• Blood tests limited to patients who decline stool or colonoscopy
• Guidelines target low screening rates in 45‑49 age group
• Positive stool or blood results must be followed by colonoscopy

Pulse Analysis

The American Cancer Society’s revised colorectal cancer screening recommendations reflect a pragmatic shift toward tests that patients are more likely to complete. By adding a next‑generation DNA stool assay and a multi‑target RNA stool test, the guidelines broaden the non‑invasive toolkit with methods that demonstrate high sensitivity for cancer and moderate sensitivity for advanced precancerous lesions. These stool‑based options retain the convenience of at‑home collection while offering diagnostic performance that rivals traditional fecal immunochemical tests, positioning them as attractive first‑line choices for average‑risk adults.

Equally important, the panel placed clear limits on blood‑based screening, reserving it for individuals who refuse all other modalities. Although patient surveys show a strong preference for blood draws—over half would choose a three‑year blood test over annual stool testing—the evidence indicates lower detection rates for early disease. By framing blood tests as a secondary fallback, the guidelines balance patient preference with clinical efficacy, encouraging clinicians to discuss trade‑offs transparently and to ensure that any positive blood result leads to a diagnostic colonoscopy.

The updated guidance arrives amid a troubling rise in colorectal cancer among adults under 50, a demographic where screening rates lag dramatically. By expanding accessible, high‑performance stool tests, the ACS hopes to narrow the screening gap that currently leaves nearly one‑third of adults unscreened, and twice that proportion among 45‑ to 49‑year‑olds. Health systems, diagnostic manufacturers, and insurers will need to adapt to the new preferred tests, potentially reshaping reimbursement models and driving investment in stool‑based assay development. Ultimately, the recommendations aim to lower mortality by catching disease earlier and ensuring that more people complete a screening test that fits their lifestyle.